吉西他滨联合替吉奥在胰腺癌术后患者中的应用效果  

Application effect of gemcitabine combined with S-1 in patients with pancreatic cancer after surgery

作　　者：王丹[1] 杨光[1] 刘烨 罗翠 WANG Dan;YANG Guang;LIU Ye;LUO Cui(Ward I,Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,He’nan,China)

机构地区：[1]郑州大学第一附属医院肿瘤科一病区,郑州4500520

出　　处：《癌症进展》2024年第10期1097-1099,1104,共4页Oncology Progress

摘　　要：目的探讨吉西他滨联合替吉奥在胰腺癌术后患者中的应用效果。方法根据术后治疗方法的不同将86例胰腺癌患者分为对照组(n=42)和观察组(n=44),对照组患者于术后第6周接受替吉奥治疗,观察组患者在对照组的基础上联合吉西他滨治疗。比较两组患者的临床疗效、肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)、细胞迁移诱导透明质酸结合蛋白(CEMIP)]水平、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+))及不良反应发生情况。结果观察组患者的总有效率为45.45%,高于对照组患者的21.43%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CEA、CA125、CEMIP水平均低于本组治疗前,观察组患者CEA、CA125、CEMIP水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平均高于本组治疗前,CD8^(+)水平均低于本组治疗前,观察组患者CD3^(+)、CD4^(+)水平均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论吉西他滨联合替吉奥应用于胰腺癌术后患者,可提高临床疗效,降低血清肿瘤标志物水平,改善免疫功能,且不增加不良反应。Objective To investigate the application effect of gemcitabine combined with S-1 in patients with pancre-atic cancer after surgery.Method A total of 86 patients with pancreatic cancer were divided into control group(n=42)and observation group(n=44)according to different postoperative treatment methods.Patients in the control group re-ceived S-1 treatment at the 6th week after surgery,and patients in the observation group received gemcitabine treatment on the basis of the control group.The clinical efficacy,tumor markers[carbohydrate antigen 125(CA125),carcinoembry-onic antigen(CEA),cell migration inducing hyaluronan binding protein(CEMIP)]levels,immune function indicators(CD3^(+),CD4^(+),CD8^(+))and the occurrence of adverse reactions were compared between the two groups.Result The total effective rate of the observation group was 45.45%,which was higher than 21.43%of the control group,the difference was statistically significant(P<0.05).After treatment,the CEA,CA125 and CEMIP levels in both groups were lower than those before treatment,and the CEA,CA125 and CEMIP levels in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in both groups were higher than those before treatment,the levels of CD8^(+)were lower than those before treatment,and the levels of CD3^(+)and CD4^(+)in observation group were higher than those in control group,while the level of CD8^(+)was lower than that in control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Gemcitabine combined with S-1 can improve clinical efficacy,reduce serum tumor marker levels,and improve immune function without increasing adverse re-actions in patients with pancreatic cancer after surgery.

关 键 词：胰腺癌 吉西他滨 替吉奥 临床疗效 肿瘤标志物 免疫功能 

分 类 号：R735.9[医药卫生—肿瘤]